What Do FAERS Reports Show About Reglan and Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

Legacy of General Health and Science Information

If you or someone you know has developed uncontrollable facial or body movements after taking Reglan, you may be concerned about tardive dyskinesia. The medical community has long studied adverse drug reactions, and the FDA Adverse Event Reporting System (FAERS) provides a key source of data on this potential link. This page reviews what FAERS reports indicate about the association between Reglan and tardive dyskinesia.

Find Out If You Qualify for Compensation →

Bridge from General Awareness to Specific Risk

Building on the legacy of general health awareness, the specific concern regarding Reglan (metoclopramide) and its association with tardive dyskinesia (TD) emerges from clinical and occupational settings. Reglan is a medication approved for short-term treatment of symptomatic gastroesophageal reflux and diabetic gastroparesis in adults. However, its use carries a well-documented risk of causing TD, a potentially irreversible movement disorder. This section examines the clinical presentation of TD, the pharmacology of Reglan, the mechanistic pathways linking the drug to TD, and the risk considerations for affected patients, based solely on the provided evidence.

Clinical Presentation and Pharmacology of Reglan

Tardive dyskinesia is characterized by involuntary, repetitive movements, typically of the face, tongue, and extremities. The condition can be disfiguring and, in many cases, irreversible. According to the FDA-approved labeling for Reglan, metoclopramide can cause TD, which is described as 'a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan's active ingredient, metoclopramide, is a dopamine D2-receptor blocking agent. This mechanism of action is central to its therapeutic effects in the gastrointestinal tract but also underlies its potential to cause extrapyramidal side effects, including TD. As noted in a case report, 'Due to their mechanism of action, these drugs can lead to extrapyramidal side effects such as tardive dyskinesia' (https://pubmed.ncbi.nlm.nih.gov/34712535/). By blocking dopamine receptors in the brain, metoclopramide disrupts normal motor control pathways, leading to the abnormal involuntary movements characteristic of TD.

Risk Factors and Duration of Use

The risk of developing TD from Reglan is directly linked to the duration of treatment and total cumulative dosage. The boxed warning on the Reglan label states: 'The risk of developing TD increases with duration of treatment and total cumulative dosage' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum recommended treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the labeling advises avoiding treatment longer than 12 weeks, and if longer use is unavoidable, routine monitoring for TD symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The timeline between exposure to Reglan and the onset of TD can vary. While TD is often associated with prolonged use, cases have been reported after a single dose. A case report describes a gynecological patient who developed dyskinetic movements after intraoperative administration of a single dose of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This highlights that TD can occur even with short-term exposure, though the risk is higher with longer treatment.

Management and Causation Considerations

For patients who develop signs or symptoms of TD, immediate discontinuation of Reglan is required. The boxed warning states: 'Immediately discontinue Reglan in patients who develop signs or symptoms of TD' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is also contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The adequacy of warnings regarding Reglan and TD is addressed in the labeling, which includes a boxed warning, a dedicated section on TD in the Warnings and Precautions, and specific contraindications. However, the occurrence of TD after a single dose, as documented in the case report, suggests that even with these warnings, the risk may not be fully appreciated in all clinical settings. Causation considerations for affected patients involve establishing a temporal relationship between Reglan use and the onset of TD, as well as ruling out other potential causes. The case report notes that the patient had several risk factors for TD, which may have contributed to the development of the condition after a single dose (https://pubmed.ncbi.nlm.nih.gov/34712535/). This underscores the importance of assessing individual risk factors, such as age, gender, and concomitant use of other drugs that can cause TD, before prescribing Reglan. The labeling advises avoiding concomitant use of other drugs known to cause TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, the evidence clearly establishes that Reglan (metoclopramide) can cause tardive dyskinesia, a serious and potentially irreversible movement disorder. The risk increases with longer treatment duration and higher cumulative doses, but cases have been reported after short-term use. The FDA-approved labeling provides explicit warnings and guidance for minimizing risk, including using the shortest effective treatment duration, avoiding use in patients with a history of TD, and discontinuing the drug immediately if TD symptoms appear. For patients who develop TD, the condition may be irreversible, highlighting the importance of careful risk-benefit assessment before initiating Reglan therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does Reglan cause tardive dyskinesia?

Yes, Reglan (metoclopramide) can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved labeling includes a boxed warning about this risk, which increases with longer treatment duration and higher cumulative doses. Cases have been reported even after short-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the symptoms of tardive dyskinesia from Reglan?

Symptoms include involuntary, repetitive movements of the face, tongue, and extremities. These movements can be disfiguring and may not reverse even after stopping the drug. The labeling describes TD as 'a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

How long does it take for Reglan to cause tardive dyskinesia?

The risk increases with duration of treatment, but TD can occur after short-term use. A case report documented TD after a single dose of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). The labeling advises using the shortest effective treatment duration, with a maximum of 12 weeks for gastroesophageal reflux.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.